Nightingale Health and Terveystalo have entered a new agreement that extends the use of the former’s blood analysis to all customer segments of Terveystalo.
The agreement builds on their initial collaboration from 2021.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Nightingale Health’s blood analysis uses a single sample to offer risk evaluations for several chronic diseases with a single test.
According to Nightingale Health, more than 200,000 people in Finland have obtained Nightingale test results as part of Terveystalo’s occupational health checks.
Since last year, this analysis has been included in occupational health services.
Terveystalo preventive health care and obesity care medical director Ilse Rauhaniemi said: “Preventive health is at the core of Terveystalo’s operations. Collaboration with an innovative technology company has provided our customers with unique insight into their own health and health promotion.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Terveystalo and Nightingale share a vision of transferring the focus even more strongly toward disease prevention. This new agreement strengthens our preventive services and enables broader adoption of scalable and cost-effective methods in clinical practice.”
Terveystalo claims to be the largest private healthcare service provider in Finland by revenue.
The company is said to provide a range of primary care, well-being services to private individuals, corporate clients, and public sector organisations.
Terveystalo’s digital health services are claimed to be accessible at all times, and its network includes around 360 clinics and 17 hospitals across Finland.
In Sweden, the company provides occupational health services at around 140 locations.
Nightingale Health operates internationally, with its parent company in Finland and subsidiaries in the US, UK, Singapore, and Japan.
Nightingale Health founder CEO Teemu Suna said: “Our work with Terveystalo has shown that prevention can be integrated into daily care for hundreds of thousands of people.
“Expanding this partnership allows us to extend that impact across all customers of Terveystalo, making proactive health a standard part of healthcare delivery.”
In January 2024, Terveystalo announced the renewal of its health checks by incorporating Nightingale Health’s blood analysis technology into routine occupational health assessments.
